Acetanilide and paracetamol pharmacokinetics before and during phenytoin administration: genetic control of induction?

1 Steady state plasma concentrations (SSPCs) of acetanilide (AA) and its metabolite, paracetamol (PL), were studied in 27 healthy volunteer subjects before and at the end of an 11-day exposure to phenytoin (DPH). Plasma concentrations of DPH were estimated. Plasma concentrations of DPH varied from 5.1 to 20.4 microgram ml-1 (mean +/- s.e.mean 12.2 +/- 0.9). 2 The SSPC of AA before exposure to DPH varied from 0.06 to 0.67 microgram ml-1 (mean +/- s.e.mean 0.24 +/- 0.02), and following exposure from 0.03 to 0.47 microgram ml-1 (mean +/- s.e.mean 0.15 +/- 0.02). 3 The SSPC of PL before exposure to DPH varied from 1.2 to 4.4 microgram ml-1 (mean +/- s.e.mean 2.7 +/- 0.13), and following exposure from 1.1 to 3.8 microgram ml-1 (mean +/- s.e.mean 2.2 +/- 0.13). 4 SSPCs of AA and of PL decreased significantly during DPH administration (P less than 0.01 for AA, P less than 0.001 for PL). 5 Correlations were observed between the SSPCs of the drugs measured, suggesting a common influence on their kinetics. 6 Similarity was observed between the changes in plasma levels of AA and PL following DPH ingestion. There was, however, wide inter-subject variability in this regard. In some subjects no change was observed even though they had DPH demonstrable in their plasma. Consequently it may be speculated that the effects of DPH may be under genetic control.

[1]  D. Evans,et al.  Inducibility of aryl hydrocarbon hydroxylase in cultured human lymphocytes: a study of repeatability. , 1978, Journal of medical genetics.

[2]  M. Horning,et al.  Elimination of antipyrine and benzo[a]pyrene metabolism in cultured human lymphocytes , 1976, Clinical pharmacology and therapeutics.

[3]  J. Baty,et al.  A method for the estimation of acetanilide, paracetamol and phenacetin in plasma and urine using mass fragmentography. , 1976, Biomedical mass spectrometry.

[4]  L. Endrenyi,et al.  Comparative drug elimination capacity in man‐glutethimide, amobarbital, antipyrine, and sulfinpyrazone , 1973, Clinical pharmacology and therapeutics.

[5]  G. Kellermann,et al.  Genetic variation of aryl hydrocarbon hydroxylase in human lymphocytes. , 1973, American journal of human genetics.

[6]  S. Thorgeirsson,et al.  Individual differences in the plasma half-lives of lipid soluble drugs in man. , 2009, Acta pharmacologica et toxicologica.

[7]  E. Vesell,et al.  Genetic control of the phenobarbital-induced shortening of plasma antipyrine half-lives in man. , 1969, The Journal of clinical investigation.

[8]  F. Sjöqvist,et al.  A comparative study of the metabolism of desmethylimipramine, nortriptyline, and oxyphenylbutazone in man , 1969, Clinical pharmacology and therapeutics.

[9]  B. Brodie,et al.  The fate of acetanilide in man. , 1948, The Journal of pharmacology and experimental therapeutics.

[10]  H. B. Lewis,et al.  A comparative study of the metabolism of alpha-alanine, beta-alanine, serine, and isoserine; glycogen content of the liver after oral administration of the amino acids. , 1947, The Journal of biological chemistry.